OrthoAccel Technologies' AcceleDent System receives award for excellence in design

NewsGuard 100/100 Score

OrthoAccel Technologies, Inc. announced this week that it received a Bronze Award at the 23rd Annual Excellence in Design competition.  The AcceleDent System, which is an acceleration device to enhance orthodontics, was recognized by Appliance Design magazine in the Medical, Laboratory, & Test Equipment category.

Winners will be showcased in the June 2010 issue of Appliance Design.  Other winners included Philips Healthcare Respironics BiliChek and Medtronic Hydrodebrider System.

The AcceleDent System is currently being sold to select orthodontic specialists in the United Kingdom and Australia through a limited release market program.  The lightweight device is intended for 20 minutes of daily use.  Patients simply bite down on the Mouthpiece to hold it in place, which allows freedom of the hands to engage in other routine, daily activities during the treatment session.  Patients have reported using the device while engaged in a variety of activities, including homework and commuting to work.

Mike Lowe, CEO of OrthoAccel commented, "We are especially proud to have been recognized in the product's first year with its first generation design.  An important reality through the market introduction process has been that we are not developing a product – rather, we are developing a daily use experience for patients.  Significant credit goes to Bryce Rutter and team at Metaphase Design Group, our partners in creating AcceleDent."

In addition to the Mouthpiece, which connects to an Activator to deliver a light, pulsing force, the AcceleDent System includes a Travel Shell for convenience, and a Charging Port to recharge the device battery and provide compliance usage information that is captured by a microprocessor in the Activator.

The Excellence in Design nominee products were judged on four criteria: aesthetics, human factors, innovation, and technical merits.

OrthoAccel is anticipating the conclusion of another US clinical trial at the UT Health Science Center in San Antonio with a target completion date later in 2010.


OrthoAccel Technologies, Inc.


The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.
Post a new comment

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.

You might also like...
Study demonstrates link between disrupted developmental dopamine signaling and ASD